Huisarts en wetenschap

, Volume 57, Issue 1, pp 34–38

Oesofaguscarcinoom

  • Christine Kestens
  • Richard van Hillegersberg
  • Peter Siersema
Nascholing

Samenvatting

Kestens C, Van Hillegersberg R, Siersema PD. Oesofaguscarcinoom. Huisarts Wet 2014;57(1):34-8.

Het slokdarm- of oesofaguscarcinoom komt in westerse landen steeds vaker voor. De stijging komt vooral op het conto van adenocarcinomen, met barrettoesofagus als belangrijke risicofactor. Door nieuwe behandeltechnieken is de overleving voor zowel het adeno- als het plaveiselcelcarcinoom wel verbeterd, maar de mortaliteit blijft hoog. Als de tumor niet is ingegroeid in vitale organen en nog geen metastasen heeft ontwikkeld, is chirurgische resectie de aangewezen behandeling. Minimaal invasieve technieken zijn daarbij sterk in opmars, maar veelal voorbehouden aan gespecialiseerde centra. Neoadjuvante radio- en chemotherapie voor de operatie vergroot de overlevingskans.

Patiënten in een vergevorderd stadium of met een slechte algemene conditie krijgen een individuele palliatieve behandeling, bestaande uit chemotherapie, al dan niet gecombineerd met radiotherapie. Bij dysfagie kan een stent worden geplaatst, zodat eten mogelijk blijft.

kanker nascholing maagdarmaandoeningen 

Abstract

Kestens C, Van Hillegersberg R, Siersema PD. Oesophageal cancer. Huisarts Wet 2014;57(1):34-8.

Oesophageal cancer is becoming more common in Western countries. This increase is due to adenocarcinomas, with Barrett’s oesophagus as important risk factor. Although new treatment modalities have improved the survival of patients with adenocarcinoma or basal cell carcinoma, mortality still remains high. Surgical resection is indicated if the tumour has not invaded vital organs and there are no metastases. Minimally invasive techniques are becoming popular but are usually used in specialized centres only. Neoadjuvant radiotherapy or chemotherapy before surgery improves survival. Patients with advanced cancer or with a poor general condition should be offered palliative therapy, consisting of chemotherapy with or without additional radiotherapy. A stent can be placed in patients with dysphagia, so that they can eat.

Literatuur

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.PubMedCrossRefGoogle Scholar
  2. 2.
    Van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett’s oesophagus in the general population. Gut 2005;54:1062–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in The Netherlands: A nation-wide registry of pathology reports. Scand J Gastroenterol 2007;42:17–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol 2011;26:739–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, Van Dekken H, et al. Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study. Am J Gastroenterol 2011;106:1231–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012;61:970–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Dikken JL, Lemmens VE, Wouters MW, Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer 2012;48:1624–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Siersema P, Van Berge Henegouwen M, Bühre W, Dullemen HM, Van der Gaast A, Hage M, et al. Oesofaguscarcinoom: Landelijke richtlijn, Versie 3.0. Utrecht: Vereniging van Integrale Kankercentra, 2010. www.oncoline.nl/oesofaguscarcinoom, geraadpleegd juni 2013.Google Scholar
  10. 10.
    Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009;41:751–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005;23:4490–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Fujishiro M, Yahagi N, Kakushima N, Kodashima S, Muraki Y, Ono S, et al. Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol 2006;4:688–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008;57:1200–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Dig Dis Sci 2012;57:2625–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012;143:576–81.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Konda VJ, Waxman I. Endotherapy for Barrett’s esophagus. Am J Gastroenterol 2012;107:827–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277–88.PubMedCrossRefGoogle Scholar
  18. 18.
    Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol 2009;15:5983–91.PubMedCrossRefGoogle Scholar
  19. 19.
    Boonstra JJ, Kok TC, Wijnhoven BP, Van Heijl M, Van Berge Henegouwen MI, Ten Kate FJ, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 2011;11:181–8.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Van Hagen P, Hulshof, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, Van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: Five-year survival of a randomized clinical trial. Ann Surg 2007;246:992–1000.PubMedCrossRefGoogle Scholar
  22. 22.
    Hulscher JB, Van Sandick JW, De Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, et al. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol 2006;1:252–9.PubMedGoogle Scholar
  24. 24.
    Tong DK, Law S, Kwong DL, Wei WI, Ng RW, Wong KH. Current management of cervical esophageal cancer. World J Surg 2011;35:600–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Verhage RJ, Hazebroek EJ, Boone J, Van Hillegersberg R. Minimally invasive surgery compared to open procedures in esophagectomy for cancer: a systematic review of the literature. Minerva Chir 2009;64:135–46.PubMedGoogle Scholar
  26. 26.
    Butler N, Collins S, Memon B, Memon MA. Minimally invasive oesophagectomy: current status and future direction. Surg Endosc 2011;25:2071–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Biere SS, Van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Watanabe M, Baba Y, Nagai Y, Baba H. Minimally invasive esophagectomy for esophageal cancer: an updated review. Surg Today 2013;43:237–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Dikken JL, Van Sandick JW, Allum WH, Johansson J, Jensen LS, Putter H, et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg 2013;100:83–94.PubMedCrossRefGoogle Scholar
  30. 30.
    Van Vliet EP, Eijkemans MJ, Poley JW, Steyerberg EW, Kuipers EJ, Siersema PD. Staging of esophageal carcinoma in a low-volume EUS center compared with reported results from high-volume centers. Gastrointest Endosc 2006;63:938–47.PubMedCrossRefGoogle Scholar
  31. 31.
    Van Vliet EP, Hermans, Faasse C, et al. Radiologist experience and CT examination quality determine metastasis detection in patients with esophageal or gastric cardia cancer. Eur Radiol 2008;18:2475–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: Multicentre randomised trial. Lancet 2004;364:1497–504.PubMedCrossRefGoogle Scholar
  33. 33.
    Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Hammerlid E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 2005;18:131–9.PubMedCrossRefGoogle Scholar
  34. 34.
    De Wijkerslooth LR, Vleggaar FP, Siersema PD. Endoscopic management of difficult or recurrent esophageal strictures. Am J Gastroenterol 2011;106:2080-91; quiz 2092.PubMedCrossRefGoogle Scholar

Copyright information

© Bohn, Stafleu van Loghum 2014

Authors and Affiliations

  • Christine Kestens
    • 1
  • Richard van Hillegersberg
    • 1
  • Peter Siersema
    • 1
  1. 1.afdeling Maag-, Darm- en LeverziektenUMCUtrechtThe Netherlands

Personalised recommendations